Navigation Links
Gliknik Adds Incyte President & CEO Paul A. Friedman to its Board of Directors
Date:2/25/2013

BALTIMORE, Feb. 25, 2013 /PRNewswire/ -- Gliknik Inc., a privately held biopharmaceuticals company, today announced the appointment of Incyte Corporation President and Chief Executive Officer Paul A. Friedman, M.D., to its Board of Directors. Dr. Friedman, a seasoned pharmaceutical industry executive with strong experience in management of R&D and corporate functions, joins Gliknik's board as the company is continuing to advance its pipeline of drug candidates targeting various cancers and immune disorders.

"It's an honor for us to welcome Paul to the Gliknik Board of Directors," said Gliknik CEO David S. Block. "His deep experience in pharmaceutical research, development, commercialization, and business development and his unwavering commitment to excellence bring an important perspective to Gliknik as we seek to advance and to partner our pipeline of novel therapies."

Dr. Friedman joined Incyte in 2001 as Chief Executive Officer and a Director. A biopharmaceutical company focused on discovering, developing and commercializing proprietary small molecule drugs for oncology and inflammation, Incyte developed and commercialized Jakafi® (ruxolitinib) under Dr. Friedman and has a robust product pipeline. Previously, Dr. Friedman served as President of R&D for the DuPont Merck Pharmaceutical Company, President of DuPont Pharmaceuticals Research Laboratories, and Senior Vice President at Merck Research Laboratories. Prior to his work at Merck and DuPont, Dr. Friedman was an associate professor of medicine and pharmacology at Harvard Medical School. Dr. Friedman is a diplomate of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. He received his A.B. in b
'/>"/>

SOURCE Gliknik Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
2. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
3. Nephros Appoints John C. Houghton as President and Chief Executive Officer
4. Herb Baer Appointed President of Polar USA
5. SolutionStart Corp. Announces John Karagiannis as Vice President of Technology
6. Elsevier Appoints New President of Elsevier CPM Resource Center
7. GenWay Biotech Appoints New Vice President of Custom/OEM
8. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. Watson Names Lisa DeFrancesco Vice President, Global Investor Relations
11. Millstone Medical Outsourcing Hires New Vice President Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... CHINA , May 24, 2013 ... or the "Company"), a leading China ... manufacturing and marketing biopharmaceutical products, announced today that, ... "EGM"), the Company,s shareholders voted in favor of ... announced agreement and plan of merger dated February ...
(Date:5/23/2013)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) ... Life Science Firm of the Year by the Tech Council ... at the TCM,s 25 th Annual Tech Awards Celebration ... Awards Celebration recognizes the leaders and innovators in the technology ... and the surrounding regions. "We are deeply ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de ... ), un destacado desarrollador y fabricante de herramientas ... la diagnosis y tratamiento de la enfermedad vascular ... del ensayo ADVISE ( Ad enosine V ... E valuation) II durante la sesión de ensayo ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... Horror stories related to medical equipment for new construction or ... of dollars are wasted, and delays in go-live dates can ... an independent nonprofit that researches the best approaches to improving ... 6 best practices to ensure a better outcome in a ...
... Oct. 28 DUSA Pharmaceuticals, Inc.® (Nasdaq GM: ... announced today that global sales volumes of the ... Photodynamic Therapy (PDT) technology platform, surpassed one million ... that dermatologists in the U.S. and abroad continue ...
Cached Medicine Technology:Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 2Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 3DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units 2
(Date:5/23/2013)... By Denise Mann HealthDay Reporter , , THURSDAY, ... of Americans take to help treat hip and knee ... increase risk for developing glaucoma, a small new study ... there is an increase of intraocular pressure (IOP) or ... of the leading causes of blindness. ...
(Date:5/23/2013)... 2013 Memorial Day Focus Spotlight on ... been a part of the U.S. Military for more ... preceding it, these men and women will be honored ... of America. As veterans transition to civilian life, ... the workplace chaplaincy world. , Marketplace Chaplains, America’s ...
(Date:5/23/2013)... “Talk. They Hear You.” a new national ... talk to children as young as nine years old ... by the Substance Abuse and Mental Health Services Administration ... SAMHSA’s 2013 National Prevention Week—an annual health observance dedicated ... and mental health issues. , SAMHSA’s latest report on ...
(Date:5/23/2013)... to its destruction inside a cell, a cancer-promoting ... thwart the development of tumor-suppressing microRNAs (miRNAs) before ... publication at Nature . , Under conditions ... epidermal growth factor receptor (EGFR) gums up the ... scientists at The University of Texas MD Anderson ...
(Date:5/23/2013)... carries a poor prognosis, with limited treatment options. ... the way it,s supposed to. New research from Western ... chemotherapy, and identifies a mechanism to rectify that. ... and his team at Western,s Schulich School of Medicine ... to promote the death of cancer cells by binding ...
Breaking Medicine News(10 mins):Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3Health News:New Campaign to Help Parents Talk to Younger Children About the Dangers of Underage Drinking 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3
... have arisen about the best approach whether it is public ... that more people want public services offering better health care ... Queen Elizabeth Hospital is an example financial difficulty due to ... study reveals that the health care provided by the not-for-profit ...
... a well-known fact that nearly 1/3rd of our lifetime is ... important as the quantity. People who have odd working hours ... chronic sleep deprivation that is responsible for fatigue and other ... North Polar Region have for the first time shed light ...
... the University of Washington researchers between obesity and asthma. ... the Journal of Allergy and Clinical Immunology. Previous studies ... develop asthma. The new research reveals the common genetic ... ,The researchers led by Dr. Teal Hallstrand analyzed ...
... French are reluctant to place their orders for Christmas turkeys ... ,However, the dreaded disease has not stopped the British and ... year, say industry sources. ,In France, bulk ... orders, say industry sources. The consumer confidence seems to have ...
... on bird shows in Britain has been lifted on account of ... ,Various events such as pigeon racing, falconry and other bird shows ... bird flu scare in October which was detected in Eastern Europe ... now since no single case of bird flu was reported the ...
... regarding the Christmas dinner. Turkey still remains popular inspite of the ... risen by 25% in Britain. Supermarket owners say that the sales ... ,When bird flu was spreading and was in its peak ... sales will fall very sharply. ,But the health officials ...
Cached Medicine News:Health News:Reindeer Provide Valuable Insights Into Sleep Disorders 2Health News:Christmas turkey? Anyone? 2
... KeraCel Ophthalmic Products are constructed ... of lint-free MEROCEL polyvinyl acetal ... to be beneficial to both ... absorbent, and yet firm enough ...
... KeraCel Ophthalmic Products are constructed ... of lint-free MEROCEL polyvinyl acetal ... to be beneficial to both ... absorbent, and yet firm enough ...
...
... Merocel Ophthalmic Products ... superior fiber free products ... and safe cleaning of ... exclusive Merocel material is ...
Medicine Products: